Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6193242 | 0.91 | DRD2 (0.46) | DRD2LMNAALDH1A1DRD4HTR1A | |
| SCHEMBL6193315 | 0.88 | DRD2 (0.43) | DRD2LMNAALDH1A1DRD4HTR1A | |
| SCHEMBL6192846 | 0.87 | DRD2 (0.43) | DRD2ALDH1A1DRD4HTR1AADRA1D | |
| SCHEMBL6194268 | 0.87 | DRD2 (0.43) | DRD2HTR2AALDH1A1DRD4HTR1A | |
| SCHEMBL6192783 | 0.87 | HTR1A (0.48) | DRD2ALDH1A1SMN1; SMN2DRD4HTR1A | |
| SCHEMBL6192202 | 0.87 | DRD2 (0.44) | DRD2LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6195679 | 0.86 | DRD2 (0.41) | DRD2HTR2AMAPTALDH1A1MAPK1 | |
| SCHEMBL6211824 | 0.85 | DRD4 (0.49) | DRD2ALDH1A1SMN1; SMN2DRD4HTR1A | |
| SCHEMBL6194533 | 0.84 | DRD2 (0.43) | DRD2LMNAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6192716 | 0.83 | DRD2 (0.42) | DRD2DRD4HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | claimed |
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | DRD2 163/4885HTR2A 8/4885LMNA 2397/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | DRD2 85/4885HTR2A 8/4885LMNA 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.